1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000 Feb 15;88(4):921–32.
3. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1357–62.
4. The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group*. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis. JAMA. 2010 May 5;303(17):1729–37.
5. Wu D-M, Wang S, Wen X, Han X-R, Wang Y-J, Shen M, et al. Survival Benefit of Three Different Therapies in Postoperative Patients With Advanced Gastric Cancer: A Network Meta-Analysis. Front Pharmacol [Internet]. 2018 [cited 2021 Jun 27];9. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2018.00929/full
6. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 1989 Apr 15;49(8):1996–2001.
7. Gunduz N, Fisher B, Saffer EA. Effect of Surgical Removal on the Growth and Kinetics of Residual Tumor. Cancer Res. 1979 Oct 1;39(10):3861–5.
8. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: Part I. J Surg Oncol. 1995;60(2):137–46.
9. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725–30.
10. Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, et al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Oct 4;35(32):3671–7.
11. Gao P, Huang X, Song Y, Sun J, Chen X, Sun Y, et al. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study. BMC Cancer. 2018 Mar 1;18(1):234.
12. Bos ACRK, van Erning FN, van Gestel YRBM, Creemers GJM, Punt CJA, van Oijen MGH, et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer. 2015 Nov 1;51(17):2553–61.
13. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. JAMA Oncol. 2016 Mar;2(3):322–9.
14. Park HS, Jung M, Kim HS, Kim H-I, An JY, Cheong J-H, et al. Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. Ann Surg Oncol. 2015 Jan 1;22(1):224–31.
15. Greenleaf EK, Kulaylat AN, Hollenbeak CS, Almhanna K, Wong J. Timing of Adjuvant Chemotherapy and Impact on Survival for Resected Gastric Cancer. Ann Surg Oncol. 2016 Dec;23(13):4203–13.
16. Harless W, Qiu Y. Cancer: A medical emergency. Med Hypotheses. 2006 Jan 1;67(5):1054–9.
17. Zhan Q-H, Fu J-Q, Fu F-M, Zhang J, Wang C. Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget. 2017 Dec 7;9(2):2739–51.
18. Huang S-M, Chen Y-C, Chen W-Y, Yang L-Y, Tsan D-L, Tsang N-M, et al. Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. J Cancer. 2019 Jan 1;10(2):332–40.
19. Kang SY, Ahn MS, Song GW, Choi YW, Lee HW, Jeong SH, et al. Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome? Acta Oncol. 2015 Sep 14;54(8):1231–4.
20. Ahn GT, Baek SK, Han JJ, Kim HJ, Jeong SJ, Maeng CH. Optimal time interval from surgery to adjuvant chemotherapy in gastric cancer. Oncol Lett. 2020 Oct 1;20(4):1–1.
21. Petrelli F, Zaniboni A, Ghidini A, Ghidini M, Turati L, Pizzo C, et al. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. Cancers. 2019 Apr;11(4):550.
22. Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, et al. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer. 2018 May 1;21(3):446–52.
23. Di Bartolomeo M, Pietrantonio F, Rulli E, Poli D, Berenato R, Caporale M, et al. Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer. Tumori J. 2016 Jul 1;102(4):e15–9.